Newswise – Researchers have identified a gene TDRD7 As a major regulator against influenza A virus (IAV), which causes respiratory infections in 5 to 20 percent of the population. These findings could facilitate the development of new therapeutic interventions against influenza virus infection. The study, which was led by the Icahn School of Medicine at Mount Sinai in collaboration with other institutions, was published in science progress On October 5.
IAV is responsible for 250,000-500,000 deaths annually worldwide. When an IAV infects its host, it initiates an immune response consisting of a series of molecular processes. IAV can infect several different species, and physiological and genetic differences between these species can contribute to different host responses, although some responses are involved.
said Ben Chang, PhD, director of the Center for Transformational Disease Modeling, Willard T. C. Johnson Professor of Neurogenetics, and Icahn Mount Sinai Professor of Genetics and Genomics, who led the study.
The study used RNA sequencing to analyze gene expression over time in cells and tissues collected from humans, rodents and mice infected with IAV, identifying multiple key defense processes that are specific to tissues and species. One gene found to play a key role in immune defense mechanisms against IAV across all species was TDRD7, which encodes a Tudor domain-containing protein, a type of protein shown to be involved in the regulation of epigenetics. In light of this discovery, the researchers conducted subsequent experiments that inhibit the function of TDRD7, This resulted in increased virus replication in IAV-infected models.
said Christian Forrest, PhD, assistant professor of genetics and genomics sciences, and microbiology, at Icahn Mount Sinai and first author of the study.
Co-authors on the research team also include Laura Martin Sancho, Ph.D., a scientist at Scripps Research, California, and Shashank Tripathi, Ph.D., Assistant Professor, Microbiology and Cell Biology, Infectious Disease Research Center, Indian Institute of Science, Bangalore. Also among the senior authors on the research team are Adolfo García Sastre, MD, Irene, Dr. Arthur M. Fishberg Professor of Medicine and Director of Institute of global health and emerging pathogens at Icahn Mount Sinai in New York, and Elodie Gaden, Ph.D., chair of the division of systems genomics and deputy chief of the Laboratory of Parasitic Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health.
This study was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under award numbers R21AI149013, U01AI111598, U19AI106754, U19AI135972, U19AI142733, U19AI168631, and NIAID funding. Influenza Research Center (CRIP) and Center of Excellence for Influenza Research and Response (CEIRR, Contract No. 75N93021C00014).
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally known for its outstanding research, educational programs, and clinical care. It is the only academic partner of the eight-member hospitals* in the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse number of patients.
Ranked 14th nationwide in National Institutes of Health (NIH) funding and among the 99 percent of research dollars per researcher according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 scientists, educators and clinicians work full-time within and across 34 academic departments and 35 interdisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our focus on research and therapeutics is evident in areas as diverse as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastroenterology and hepatology.
Icahn Mount Sinai offers highly competitive master’s, doctoral, and master’s programs, with a current enrollment of around 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the health system. In addition, more than 550 postdoctoral researchers are trained in the health system.
A culture of innovation and discovery permeates every Icahn Mount Sinai program. The Mount Sinai Office of Technology Transfer, one of the largest in the country, collaborates with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations are translated into health care products and services that benefit the public.
Icahn Mount Sinai’s commitment to advancing science and clinical care is underpinned by academic affiliations that complement and complement the school’s programs.
Through the Mount Sinai Innovation Partners (MSIP), the health system facilitates the real-world application and commercialization of the medical achievements of Mount Sinai. In addition, MSIP develops research partnerships with industry leaders such as Merck & Co. And AstraZeneca, Novo Nordisk, and others.
The Icahn School of Medicine is located in Mount Sinai in New York City on the border between the Upper East Side and East Harlem, and classroom instruction takes place on a campus facing Central Park. Icahn Mount Sinai provides many opportunities to interact with and care for diverse communities. Learning extends beyond the confines of the actual campus, to the eight hospitals affiliated with the Mount Sinai Health System, our academic affiliates, and globally.
* Hospitals that are members of the health system in Mount Sinai: Mount Sinai Hospital. Mount Sinai, the house of Israel; Mount Sinai Brooklyn Mount Sinai Morningside. Queens of Mount Sinai. Mount Sinai south of Nassau; Mount Sinai west; And the New York eye and ear clinic in Mount Sinai.